Chemo-free triplet aims to outsmart incurable lymphoma
NCT ID NCT07550855
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a chemotherapy-free combination of three drugs (sonrotoclax, zanubrutinib, and rituximab) in 52 adults with previously untreated follicular lymphoma. The goal is to see if this approach can produce deeper and longer-lasting remissions while being easier to tolerate than standard chemo. Participants must have advanced-stage disease and meet certain health criteria.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA (FL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen Universitiy Cancer Center
Guangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Three-Drug cocktail replace chemo for follicular lymphoma?
- New drug combo aims to outsmart recurring lymphoma
- New combo pill attack aims to control blood cancers
- Smart blood pressure cuffs could protect cancer patients from heart risks
- New cell therapy CT1182 takes on tough lymphoma
- New hope for Tough-to-Treat lymphoma: experimental drug combo enters phase 3 trial